Bill Text: NJ ACR100 | 2018-2019 | Regular Session | Introduced
Bill Title: Urges federal government to allow additional entities to retain pharmaceutical products beyond expiration date.
Spectrum: Partisan Bill (Democrat 1-0)
Status: (Introduced - Dead) 2018-01-29 - Introduced, Referred to Assembly Oversight, Reform and Federal Relations Committee [ACR100 Detail]
Download: New_Jersey-2018-ACR100-Introduced.html
ASSEMBLY CONCURRENT RESOLUTION No. 100
STATE OF NEW JERSEY
218th LEGISLATURE
INTRODUCED JANUARY 29, 2018
Sponsored by:
Assemblyman GARY S. SCHAER
District 36 (Bergen and Passaic)
SYNOPSIS
Urges federal government to allow additional entities to retain pharmaceutical products beyond expiration date.
CURRENT VERSION OF TEXT
As introduced.
A Concurrent Resolution urging the federal government to allow additional entities to retain pharmaceutical products beyond expiration date.
Whereas, The federal Food and Drug Administration (FDA) requires that all pharmaceutical products include an expiration date, which is intended to reflect the maximum period of time for which the manufacturer guarantees the product will remain at least 90 percent effective; and
Whereas, Manufacturers determine pharmaceutical expiration dates using stability testing, which involves exposing the product to extreme heat and moisture to determine how it degrades under stress and over time; and
Whereas, Manufacturers submit a proposed expiration date to the FDA, which will approve the date after confirming that it is supported by the available data. Expiration dates are typically set at one to five years after the date of manufacture; and
Whereas, Even after a pharmaceutical product is launched, manufacturers continue to test the product to confirm that the approved expiration date reflects a period during which the medication continues to be at least 90 percent effective. However, they do not currently evaluate whether expiration dates can be extended; and
Whereas, Generally, federal law requires pharmacies, government agencies, and other entities that maintain stockpiles of pharmaceutical products to dispose of products that have reached the labeled expiration date; and
Whereas, In 1986, as a cost-saving measure, the FDA and the Department of Defense (DOD) created the Shelf Life Extension Program to determine whether the expiration dates for various drugs could be extended. At least one study conducted under the program determined that approximately two-thirds of the 122 drugs tested remained stable past the approved expiration date, and, on average, these drugs remained at least 90 percent effective for more than four years after the expiration date; and
Whereas, As a result of the study, a number of federal entities, including the federal Centers for Disease Control and Prevention, the Department of Veterans Affairs, and the military, are permitted to retain stockpiles of certain medications beyond the approved expiration date; and
Whereas, According to one estimate, retaining pharmaceutical products beyond their expiration dates saves the federal government between $600 million and $800 million per year. Moreover, one DOD official reported that the Shelf Life Extension Program cost the DOD approximately $3.1 million to run in 2016, while netting cost savings of $2.1 billion, representing $677 in savings for each $1 spent; and
Whereas, Notwithstanding the findings of the Shelf Life Extension Program, pharmaceutical manufacturers have not opted to extend expiration dates for their products, and the FDA has not authorized entities outside the federal government to retain pharmaceutical products beyond their expiration date; and
Whereas, Requiring pharmacies and other entities to dispose of pharmaceutical supplies according to the labeled expiration date results in wasted product, drives up the cost of doing business for pharmacies, increases operational costs for law enforcement agencies, emergency medical services providers, and local and county health departments, and results in inflated prices that adversely affect health insurers and consumers alike; and
Whereas, It is therefore appropriate for the federal government to allow entities that maintain stockpiles of pharmaceutical products to retain those products beyond the expiration date, under the same terms as currently apply to various federal entities, including the federal Centers for Disease Control and Prevention, the Department of Veterans Affairs, and the military; now, therefore,
Be It Resolved by the General Assembly of the State of New Jersey (the Senate concurring):
1. The New Jersey Legislature respectfully urges the federal Food and Drug Administration, the Congress of the United States, and the President of the United States to take appropriate measures to allow entities that maintain stockpiles of pharmaceutical products to retain those products beyond the expiration date under the same terms and conditions as currently apply to various federal entities, including the federal Centers for Disease Control and Prevention, the Department of Veterans Affairs, and the military.
2. Copies of this resolution, as filed with the Secretary of State, shall be transmitted by the Clerk of the General Assembly or the Secretary of the Senate to the President and Vice President of the United States, the Commissioner of Food and Drugs, the Majority and Minority Leaders of the United States Senate, the Speaker and Majority and Minority Leaders of the United States House of Representatives, and each member of the United States Congress elected from New Jersey.
STATEMENT
This concurrent resolution respectfully urges the federal Food and Drug Administration (FDA) and the Congress and President of the United States to take appropriate measures to allow entities that maintain stockpiles of pharmaceutical products to retain those products beyond the expiration date under the same terms and conditions as currently apply to various federal entities, including the federal Centers for Disease Control and Prevention, the Department of Veterans Affairs, and the military.
Currently, pharmaceutical manufacturers propose expiration dates to the FDA that are intended to reflect the time period during which the product will remain at least 90 percent effective; the FDA approves these dates upon confirming they are supported by the available data. Pharmacies, government agencies, emergency medical response squads, county and local health departments, and other entities that stockpile pharmaceutical products are required to dispose of any products that have reached their expiration date.
In 1986, the FDA and the Department of Defense began the Shelf Life Extension Program, which found that many pharmaceutical products remain at least 90 percent effective for several years past the labeled effective date. In light of this, the federal government has allowed certain federal entities, including the Centers for Disease Control and Prevention, the Department of Veterans Affairs, and the military, to retain pharmaceutical products beyond the labeled expiration date, resulting in significant cost savings. However, this approval has not been extended to entities outside the federal government, which are still required to dispose of any product that has reached its expiration date. This results in products that are still safe and effective for use being wasted, and increases costs for pharmacies, consumers, insurers, and the various entities that maintain pharmaceutical stockpiles.
Allowing additional entities to retain stockpiles of pharmaceutical products beyond their expiration dates, consistent with current studies and on the same terms as various federal entities are authorized to do, would be a significant step in helping realize cost savings in the pharmaceutical market, both within New Jersey and throughout the nation.
